Raloxifene, a selective estrogen receptor modulator, inhibits lipopolysaccharide-induced nitric oxide production by inhibiting the phosphatidylinositol 3-kinase/Akt/nuclear factor-kappa B pathway in RAW264.7 macrophage cells

Molecules and Cells

Volumn 26, Issue 1, 2008, Pages 48-52

  Lee, Sin Ae ^a   Park, Seok Hee ^b   Kim, Byung Chul ^a  

^a Kangwon National University   (South Korea)

^b Sungkyunkwan University   (South Korea)

Author keywords

Anti inflammatory; Macrophages; NF B; Nitric oxide; PI 3 kinase; Raloxifene

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; NITRIC OXIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RALOXIFENE; LIPOPOLYSACCHARIDE; LUCIFERASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; NITRITE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL STRAIN; CONTROLLED STUDY; DNA BINDING; DOWN REGULATION; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME SYNTHESIS; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION REGULATION; GENE TRANSLOCATION; MACROPHAGE; NONHUMAN; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REPORTER GENE; ANIMAL; CELL CULTURE; DRUG ANTAGONISM; DRUG EFFECT; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOBLOTTING; METABOLISM; MOUSE;

MURINAE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; CELLS, CULTURED; DOWN-REGULATION; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; IMMUNOBLOTTING; LIPOPOLYSACCHARIDES; LUCIFERASES; MACROPHAGES; MAP KINASE KINASE 4; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NF-KAPPA B; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; NITRITES; PROTO-ONCOGENE PROTEINS C-AKT; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 53449086634     PISSN: 10168478     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Ariazi, E.A., Ariazi, J.L., Cordera, F., and Jordan, V.C. (2006). Estrogen receptors as therapeutic targets in breast cancer. Curr. Top. Med. Chem. 6, 195-216.
2. Cirino, G. (1998). Multiple controls in inflammation. Extracellular and intracellular phospholipase A2, inducible and constitutive cyclooxygenase, and inducible nitric oxide synthase. Biochem. Pharmacol. 55, 105-111.
3. Delmas, P.D., Bjarnason, N.H., Mitlak, B.H., Ravoux, A.C., Shah, A.S., Huster, W.J., Draper, M., and Christiansen, C. (1997). Effects od raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N. Engl. J. Med. 337, 1641-1647.
4. Eming, S.A., Krieg, T., and Davidson, J.M. (2007). Inflammation in wound repair: molecular and cellular mechanisms. J. Invest. Dermatol. 127, 514-525.
5. Esposito, E., Iacono, A., Raso, G..M., Pacilio, M., Coppola, A., Di Cario, R., and Meli, R. (2005). Raloxifene, a selective estrogen receptor modulator, reduces carrageenan-induced acute inflammation in normal and ovariectomized rats. Endocrinology 146, 3301-3308.
6. Grandage, V.L., Gale, R.E., Linch, D.C., and Khwaja, A. (2005). PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinases and p53 pathways. Leukemia 19, 586-594.
7. Grese, T.A., Sluka, J.P., Bryant, H.U., Cullinan, G.J., Glasebrook, A.L., Jones, C.D., Matsumoto, K., Palkowitz, A.D., Sato, M., Termine, J.D., et al. (1997). Molecular determinants of tissue selectivity in estrogen receptor modulator. Proc. Natl. Acad. Sci. USA 94, 14105-14110.
8. Hanada, T., and Yoshimura, A. (2002). Regulation of cytokine signaling and inflammation. Cytokine Growth Factor Rev. 13, 413-421.
9. Katznellenbogen, B.S., and Katznellenbogen, J.A. (2002). Defining the "S" in SERMS. Science 295, 2380-2381.
10. Kawagoe, J., Ohmichi, M., Takahashi, T., Ohshima, C., Mabuchi, S., Takahashi, K., Igarashi, H., Mori-Abe, A., Saitoh, M., Du, B., et al. (2003). Raloxifene inhibits estrogen-induced up-regulation of telomerase activity in a human breast cancer cell line. J. Biol. Chem. 278, 43363-43372.
11. Kuiper, G.G.J.M., Lemmen, J.G., Carlsson, B., Corton, J.C., Safe, S.H., van der Saag, P.T., vad der Burg, B., and Gustafsson, J.-A. (1998). Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor-β. Endocrinology 13, 4252-4263.
12. Laskin, D.L., and Pendino, J. (1995). Macrophages and inflammatory mediators in tissue injury. Annu. Rev. Pharmacol. Toxicol. 35, 655-677.
13. Lee, S.J., Bai, S.K., Lee, K.S., Namkoong, S., Na, H.J., Ha, K.S., Han, J.A., Yim, S.Y., Chang, K., Kwon, Y.G., et al. (2003). Astaxanthin inhibits nitric oxide production and inflammatory gene expression by suppressing I(kappa)B kinase-dependent NF-kappaB activation. Mol. Cells 16, 97-105.
14. Lonard, D.M., and Smith, C.L. (2002). Molecular perspectives on selective estrogen receptor modulators (SERM): progress in understanding their tissue-specific agonist antagonist actions. Steroid 67, 15-24.
15. Lufkin, E.G., Whitaker, M.D., Nickelsen, T., Argueta, R., Caplan, R.H., Knickerbocker, R.K., and Riggs, B.L. (1998). Treatment of established postmenopausal osteoporosis with raloxifene: A randomized trial. J. Bone Miner. Res. 13, 1747-1754.
16. Romashkova, J.A., and Makarov, S.S. (1999). NF-kappaB is a target of AKT in anti-apoptotic PDGF signaling. Nature 401, 86-90.
17. Sherman, M.P., Aeberhard, E.E., Wong, V.Z., Griscavage, J.M., and Ignarro, L.J. (1993). Pyrrolidine dithiocarbamate inhibits induction of nitric oxide synthase activity in rat alveolar macrophages. Biochem. Biophys. Res. Commun. 191, 1301-1308.
18. Shoji, T., Yoshida, S., Mitsunari, M., Miyake, N., Tsukihara, S., Iwabe, T., Harada, T., and Terakawa, N. (2007). Involvement of p38 MAP kinase in lipopolysaccharide-induced production of pro- and anti-inflammatory cytokines and prostaglandin E(2) in human choriodecidua. J. Reprod. Immunol. 75, 82-90.
19. Stuehr, D.J. (1997). Structure-function aspects in the nitric oxide synthases, Annu. Rev. Pharmacol. Toxicol. 37, 339-359.
20. Suuronen, T., Nuutinen, T., Huuskonen, J., Ojala, J., Thornell, A., and Salminen, A. (2005). Anti-inflammatory effect of selective estrogen receptor modulators (SERMs) in microglial cells. Inflamm. Res. 54, 194-203.
21. Verhaeghe, C., Remouchamps, C., Hennuy, B., Vanderplasschen, A., Chariot, A., Tabruyn, S.P., Oury, C., and Bours, V. (2007). Role of IKK and ERK pathways in intrinsic inflammation of cystic fibrosis airways. Biochem. Pharmacol. 73, 1982-1994.